{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:26Z","timestamp":1777934726141,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antineoplastic chemotherapy (ACT) is widely used, but involves significant risks due to protocol complexity and inherent toxicity. Pharmacists play a key role in validating ACT prescriptions to enhance patient safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze medication errors during ACT prescribing and describe pharmaceutical interventions performed to manage these errors at a Federal University Hospital in the Central-West region of Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>This cross-sectional study, supplemented with case reports, was conducted between January 2023 and July 2024. A total of 382 prescriptions for 208 oncology outpatients were analyzed; only prescriptions with previously identified medication errors were included in this study. Medication errors were classified as decision-making or writing errors according to the Pharmaceutical Care Network Europe (PCNE) classification and Dean et al. (2000), and categorized by severity using the NCC MERP framework. Data were extracted from an institutional database and validated by an oncology specialist pharmacist. Only deviations with potential pharmacological or clinical impact were classified as decision-making errors, excluding minor operational adjustments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Decision-making errors occurred in 91.6% (n\u2009=\u2009358\/391) of prescriptions, primarily due to inappropriate diluent volumes (91%), while writing errors were observed in 8.4% (n\u2009=\u200936\/391), mainly from missing clinical information. Pharmaceutical interventions were accepted in 99% of cases, preventing errors from reaching patients. Most errors were intercepted before administration (NCC MERP Category B), though two cases had potential clinical consequences (Category C) and one required patient monitoring due to communication issues (Category D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Specialized oncology pharmacists play a critical role in ensuring the safety of ACT prescribing. The high proportion of decision-making errors observed within this selected sample emphasizes the need for systemic improvements, such as integrated electronic prescribing and continuous pharmacist-led oversight, to reduce preventable errors and enhance patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261444589","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:46:12Z","timestamp":1776869172000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of medication errors in oncological patients: A cross-sectional study and case reports of pharmaceutical interventions in a university hospital in central-west Brazil"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4256-3490","authenticated-orcid":false,"given":"Esther","family":"Domenici Mozzer Pontes","sequence":"first","affiliation":[{"name":"Federal University of Goi\u00e1s"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Rocha Martins","sequence":"additional","affiliation":[{"name":"Federal University of Goi\u00e1s"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Augusto Souza Fernandes","sequence":"additional","affiliation":[{"name":"Federal University of Goi\u00e1s"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Ferreira","family":"Lopes","sequence":"additional","affiliation":[{"name":"Federal University of Goi\u00e1s"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"159","volume-title":"The pharmacist guide to implementing pharmaceutical care","author":"Costa FA","year":"2019","unstructured":"Costa FA, Van Mil JWF, Alvarez-Risco A. The pharmacist guide to implementing pharmaceutical care. Gewerbestrasse: Springer International Publishing AG, 2019. p. 159\u2013171, https:\/\/link.springer.com\/chapter\/10.1007\/978-3-319-92576-9_41."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00216"},{"key":"e_1_3_2_4_2","volume-title":"List of high-alert medications in acute care settings","author":"Institute for Safe Medication Practices (ISMP)","year":"2024","unstructured":"Institute for Safe Medication Practices (ISMP). List of high-alert medications in acute care settings. Horsham (PA): ISMP, 2024."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/59.17.1648"},{"key":"e_1_3_2_6_2","volume-title":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o RDC n\u00b0 220, de 21 de setembro de 2004","author":"Brasil","year":"2004","unstructured":"Brasil. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o RDC n\u00b0 220, de 21 de setembro de 2004. Bras\u00edlia: ANVISA, 2004."},{"key":"e_1_3_2_7_2","volume-title":"Guia de Manipula\u00e7\u00e3o de Antineopl\u00e1sicos","author":"Sociedade Brasileira de Farmac\u00eauticos em Oncologia","year":"2016","unstructured":"Sociedade Brasileira de Farmac\u00eauticos em Oncologia. Guia de Manipula\u00e7\u00e3o de Antineopl\u00e1sicos. 3\u00aa ed. S\u00e3o Paulo: SOBRAFO, 2016.","edition":"3"},{"key":"e_1_3_2_8_2","volume-title":"Resolu\u00e7\u00e3o n\u00b0 640, de 27 de julho de 2017","author":"Conselho Federal de Farm\u00e1cia (CFF)","year":"2017","unstructured":"Conselho Federal de Farm\u00e1cia (CFF). Resolu\u00e7\u00e3o n\u00b0 640, de 27 de julho de 2017. Bras\u00edlia: CFF, 2017."},{"key":"e_1_3_2_9_2","volume-title":"Desenvolvimento de instrumento para an\u00e1lise das prescri\u00e7\u00f5es de antineopl\u00e1sicos","author":"M\u00e9lo SGR","year":"2022","unstructured":"M\u00e9lo SGR. Desenvolvimento de instrumento para an\u00e1lise das prescri\u00e7\u00f5es de antineopl\u00e1sicos. Recife: UFPE, 2022."},{"key":"e_1_3_2_10_2","volume-title":"CID-10: Classifica\u00e7\u00e3o Estat\u00edstica Internacional de Doen\u00e7as","author":"Organiza\u00e7\u00e3o Mundial da Sa\u00fade","year":"1993","unstructured":"Organiza\u00e7\u00e3o Mundial da Sa\u00fade. CID-10: Classifica\u00e7\u00e3o Estat\u00edstica Internacional de Doen\u00e7as. Bras\u00edlia: MS, 1993."},{"key":"e_1_3_2_11_2","volume-title":"CID-11 para Estat\u00edsticas de Mortalidade e Morbidade","author":"Organiza\u00e7\u00e3o Mundial da Sa\u00fade","year":"2022","unstructured":"Organiza\u00e7\u00e3o Mundial da Sa\u00fade. CID-11 para Estat\u00edsticas de Mortalidade e Morbidade. Genebra: OMS, 2022."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.32635\/2176-9745.RBC.1959v16n20.4357"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03417.x"},{"key":"e_1_3_2_14_2","unstructured":"Pharmaceutical Care Network Europe (PCNE). Classification for drug-related problems V9.1; 2023."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/qhc.9.4.232"},{"key":"e_1_3_2_16_2","unstructured":"Brasil. Lei n\u00b0 9.787 de 10 de fevereiro de 1999. Bras\u00edlia; 1999."},{"key":"e_1_3_2_17_2","unstructured":"National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP). Types of Medication Errors; 2022."},{"key":"e_1_3_2_18_2","article-title":"Diretrizes para detec\u00e7\u00e3o precoce do c\u00e2ncer de mama no brasil","volume":"34","author":"Migowski A","year":"2018","unstructured":"Migowski A, Silva GA, Dias MBK, et al. Diretrizes para detec\u00e7\u00e3o precoce do c\u00e2ncer de mama no brasil. Cad Sa\u00fade P\u00fablica 2018; 34: e00074817.","journal-title":"Cad Sa\u00fade P\u00fablica"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.4103\/jpp.JPP_61_18"},{"key":"e_1_3_2_20_2","first-page":"276","article-title":"Methods to reduce prescription errors in chemotherapy","volume":"29","author":"K\u00e4hk\u00f6nen A","year":"2021","unstructured":"K\u00e4hk\u00f6nen A, Eestil\u00e4 S, Kvarnstr\u00f6m K, et al. Methods to reduce prescription errors in chemotherapy. J Oncol Pharm Pract 2021; 29: 276\u2013282.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221091298"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.32635\/2176-9745.RBC.2015v61n2.554"},{"key":"e_1_3_2_23_2","first-page":"1","article-title":"Acceptance of pharmacist interventions","volume":"13","author":"Durand A","year":"2022","unstructured":"Durand A, Gilibert A, Membre S, et al. Acceptance of pharmacist interventions. Front Pharmacol 2022; 13: 1\u201311.","journal-title":"Front Pharmacol"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2024.02.006"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S307001"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220943964"},{"key":"e_1_3_2_27_2","first-page":"53","article-title":"Medication errors in hematology-oncology","volume":"12","author":"Oskoyi AE","year":"2021","unstructured":"Oskoyi AE, Sharifi H, Asghari R. Medication errors in hematology-oncology. Caspian J Intern Med 2021; 12: 53\u201358.","journal-title":"Caspian J Intern Med"},{"key":"e_1_3_2_28_2","first-page":"1","article-title":"Pharmaceutical interventions in oncology","volume":"16","author":"Aguiar KS","year":"2018","unstructured":"Aguiar KS, Santos JM, Cambrussi MC, et al. Pharmaceutical interventions in oncology. Einstein (S\u00e3o Paulo) 2018; 16: 1\u20137.","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"e_1_3_2_29_2","first-page":"1","article-title":"Electronic prescription in oncology","volume":"21","author":"Falc\u00e3o DCG","year":"2025","unstructured":"Falc\u00e3o DCG, Soares ALV, Araujo-Junior HC, et al. Electronic prescription in oncology. Braz J Oncol 2025; 21: 1\u20137.","journal-title":"Braz J Oncol"},{"key":"e_1_3_2_30_2","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Protocolo de seguran\u00e7a na prescri\u00e7\u00e3o de medicamentos. Bras\u00edlia; 2013."},{"key":"e_1_3_2_31_2","first-page":"1049","article-title":"Interventions in antineoplastic therapy","volume":"28","author":"Rocha C","year":"2021","unstructured":"Rocha C, Carlotto J, Neto JZ. Interventions in antineoplastic therapy. J Oncol Pharm Pract 2021; 28: 1049\u20131055.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220915763"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231180468"},{"key":"e_1_3_2_34_2","article-title":"Assist\u00eancia farmac\u00eautica em oncologia no SUS","volume":"23","author":"Silva MJS","year":"2019","unstructured":"Silva MJS, Osorio-de-Castro CGS. Assist\u00eancia farmac\u00eautica em oncologia no SUS. Interface (Botucatu) 2019; 23: e180297.","journal-title":"Interface (Botucatu)"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjquality.u216501.w7906"},{"key":"e_1_3_2_36_2","volume-title":"Medication without harm","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Medication without harm. Geneva: WHO, 2017."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219893449"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261444589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261444589","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261444589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:43Z","timestamp":1777689163000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261444589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":36,"alternative-id":["10.1177\/10781552261444589"],"URL":"https:\/\/doi.org\/10.1177\/10781552261444589","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"10781552261444589"}}